{"filing":{"accession_number":"0001213900-26-078733","cik":"0002007702","ticker":"HKPD","company_name":"Cellyan Biotechnology Co., Ltd","form":"6-K","filing_date":"2026-07-16","report_date":null,"primary_document":"ea0298266-6k_cellyan.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007702/000121390026078733/ea0298266-6k_cellyan.htm"},"events":[{"id":18453,"run_id":16588,"accession_number":"0001213900-26-078733","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The press release discloses that Cellyan received a Nasdaq notification letter on July 14, 2026 granting an additional 180-day compliance grace period (until January 11, 2027) to regain compliance with the Nasdaq minimum $1.00 closing bid price requirement. The Company must maintain a closing bid price of at least $1.00 per share for ten consecutive business days to avoid delisting. This is a material disclosure of delisting risk under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq and would materially affect a reasonable investor's assessment of the registrant's status.","company_name":"Cellyan Biotechnology Co., Ltd","ticker":"HKPD","filing_date":"2026-07-16","form":"6-K","submitted_at":null,"items":[{"id":17266,"accession_number":"0001213900-26-078733","item_number":"EX-99.1","item_title":"ea029826601ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The press release discloses that Cellyan received a Nasdaq notification letter on July 14, 2026 granting an additional 180-day compliance grace period (until January 11, 2027) to regain compliance with the Nasdaq minimum $1.00 closing bid price requirement. The Company must maintain a closing bid price of at least $1.00 per share for ten consecutive business days to avoid delisting. This is a material disclosure of delisting risk under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq and would materially affect a reasonable investor's assessment of the registrant's status.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:32:28.043353+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17266,"accession_number":"0001213900-26-078733","item_number":"EX-99.1","item_title":"ea029826601ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The press release discloses that Cellyan received a Nasdaq notification letter on July 14, 2026 granting an additional 180-day compliance grace period (until January 11, 2027) to regain compliance with the Nasdaq minimum $1.00 closing bid price requirement. The Company must maintain a closing bid price of at least $1.00 per share for ten consecutive business days to avoid delisting. This is a material disclosure of delisting risk under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq and would materially affect a reasonable investor's assessment of the registrant's status.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:32:28.043353+00:00","company_name":"Cellyan Biotechnology Co., Ltd","ticker":"HKPD","filing_date":"2026-07-16"}]}